IFRX (InflaRx NV) Moat Score: 3/10 (As of Jul. 01, 2026)


IFRX InflaRx NV IFRX
31 GF Score
Price $2.24
! 5 Warning Signs
View Full Analysis

What is InflaRx NV Moat Score?

InflaRx NV IFRX -3.03% 31 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates IFRX with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 1,401 Biotechnology companies, InflaRx NV ranks better than 75.52% on this metric.

InflaRx NV has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

InflaRx NV has No Moat: InflaRx NV, a biotech company, faces high competition and regulatory challenges. It lacks significant market share, customer loyalty, or proprietary technology that would provide a sustainable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes InflaRx NV might have No Moat - Very weak/transient advantages.

InflaRx NV  (NAS:IFRX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

InflaRx NV Moat Score Related Terms

IFRX vs BCYC, ELDN, ZNTL: Moat Score Comparison

For the Biotechnology subindustry, InflaRx NV's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Moat Score distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Moat Score falls into.


IFRX
31GF Score
InflaRx NV IFRX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
InflaRx NV (IFRX) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, InflaRx NV ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is InflaRx NV's Moat Score too high?
InflaRx NV's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. InflaRx NV's value of 3 is 50% above this industry median. Based on the distribution chart, InflaRx NV ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Moat Score compare to BCYC and ELDN?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #343 out of 1401 companies for Moat Score. This places InflaRx NV in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. InflaRx NV's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InflaRx NV's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InflaRx NV's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For InflaRx NV (IFRX), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Other Exchanges IF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
31GF Score

Get the complete analysis for IFRX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.24
Price